Avelumab as neoadjuvant therapy in patients with urothelial non-metastatic muscle invasive bladder cancer: a multicenter, randomized, non-comparative, phase II study (Oncodistinct 004 - AURA trial)

Abstract Introduction Cisplatin-based neoadjuvant chemotherapy (NAC) followed by surgery is the standard treatment for patients with non-metastatic muscle invasive bladder cancer (MIBC). Unfortunately, many patients are not candidates to receive cisplatin due to renal impairment. Additionally, no pr...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Nieves Martinez Chanza, Louisa Soukane, Philippe Barthelemy, Aurélien Carnot, Thierry Gil, Vinciane Casert, Vincent Vanhaudenarde, Brieuc Sautois, Lionel Staudacher, Jan Van den Brande, Stephane Culine, Emmanuel Seront, Marco Gizzi, Simone Albisinni, Thibault Tricard, Jean Christophe Fantoni, Marianne Paesmans, Rafael Caparica, Thierry Roumeguere, Ahmad Awada
Formato:	Artigo
Idioma:	Inglês
Publicado em:	BMC 2021-12-01
coleção:	BMC Cancer
Assuntos:	Avelumab Bladder cancer Checkpoint inhibitor Immunotherapy Neoadjuvant PD-1 blockade
Acesso em linha:	https://doi.org/10.1186/s12885-021-08990-3
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!